How to Get Vyvanse in New Hampshire

What Vyvanse Is and Why It Requires a Controlled-Substance Pathway

Vyvanse (lisdexamfetamine dimesylate) is a prodrug stimulant the FDA approved in 2007 for ADHD and later expanded to binge eating disorder in 2015 [1]. Because the body must convert lisdexamfetamine to d-amphetamine in the gastrointestinal tract, its abuse potential is lower than immediate-release amphetamine formulations, though the DEA still classifies it as Schedule II [2]. That classification shapes every step of the prescribing and dispensing process in New Hampshire.

In a 2017 analysis by Wigal et al., lisdexamfetamine demonstrated consistent efficacy across pediatric and adult ADHD populations, with effect sizes ranging from 0.80 to 1.26 on the ADHD Rating Scale [3]. The drug's once-daily dosing and 12- to 14-hour duration of action make it a common first-line choice when clinicians and patients prefer extended coverage without a midday dose [4]. Takeda's prescribing label recommends initiating at 30 mg each morning and titrating in 10 mg or 20 mg increments at weekly intervals, up to a maximum of 70 mg/day for ADHD [1].

Step 1: Find a Licensed Prescriber in New Hampshire

Any physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) who holds an active New Hampshire license and a current DEA registration can prescribe Vyvanse. New Hampshire grants NPs full practice authority under RSA 326-B, meaning NPs can prescribe Schedule II substances independently without a collaborative agreement [5]. PAs may prescribe Schedule II drugs under their supervising physician's DEA number or their own, per NH Board of Medicine rules.

For in-person visits, search the New Hampshire Board of Medicine provider directory or contact your primary care office. Many psychiatrists and psychiatric NPs in Manchester, Concord, and Nashua carry ADHD-specific caseloads.

Telehealth is a strong option. New Hampshire's telehealth prescribing statute (RSA 329:1-d) allows a provider to establish a patient relationship via synchronous audio-video visit and prescribe Schedule II medications electronically [6]. The DEA's updated telehealth rule (published November 2024) allows practitioners who conduct an initial video evaluation to prescribe up to a 90-day supply of Schedule II controlled substances before requiring an in-person visit [7]. This means a New Hampshire resident can receive a Vyvanse prescription from a qualified telehealth provider without leaving home for the first fill.

Step 2: Complete the Required Evaluation and Labs

A proper ADHD diagnosis follows DSM-5-TR criteria: six or more symptoms of inattention and/or hyperactivity-impulsivity persisting for at least six months, with onset before age 12 and functional impairment in two or more settings [8]. Most clinicians use validated rating scales such as the ASRS v1.1 (Adult ADHD Self-Report Scale) or the Vanderbilt Assessment for pediatric patients [9].

Before starting Vyvanse, the American Academy of Pediatrics and the American Psychiatric Association recommend a baseline evaluation that includes heart rate, blood pressure, height, and weight [10]. An EKG is not routinely required for patients without cardiac history, per the AAP's 2019 guideline update [10]. Some clinicians also order a baseline CBC and metabolic panel, though this is a practice preference rather than an FDA requirement.

For binge eating disorder, diagnosis requires recurrent episodes (at least once per week for three months) with marked distress and absence of compensatory behaviors, per DSM-5-TR criteria [8]. The STEP-BD and SUCCEED trials established lisdexamfetamine's efficacy in this population, with the SUCCEED trial (N=275) showing a 3.87 mean reduction in binge days per week versus 2.51 for placebo at 12 weeks [11].

Step 3: Manage Prior Authorization in New Hampshire

Here is where the process diverges by payer. NH Medicaid (managed through the NH Department of Health and Human Services) does not cover brand-name Vyvanse on its preferred drug list as of 2026. Patients on Medicaid may need to try and fail a preferred stimulant (typically generic mixed amphetamine salts or methylphenidate) before an exception request is considered [12].

Commercial insurers such as Anthem BCBS of NH, Cigna, Harvard Pilgrim, and Ambetter frequently do cover Vyvanse or generic lisdexamfetamine, but most require prior authorization (PA). Typical PA documentation includes:

• A confirmed DSM-5-TR ADHD or BED diagnosis
• Prior trial and failure (or documented intolerance) of at least one first-line generic stimulant
• Chart notes from the prescribing provider
• Validated symptom rating scales (ASRS, Conners, or SNAP-IV)

PA turnaround times in NH average 48 to 72 hours for standard requests. Denials can be appealed through your insurer's formulary exception process; the NH Insurance Department oversees external review if internal appeals are exhausted [13].

Step 4: Fill the Prescription at a New Hampshire Pharmacy

New Hampshire accepts electronic prescribing for controlled substances (EPCS), and state law requires prescribers to check the NH Prescription Drug Monitoring Program (PDMP) before issuing a Schedule II prescription [14]. Once the e-prescription reaches the pharmacy, expect same-day or next-day dispensing if the medication is in stock.

Supply disruptions have affected stimulant medications nationally since late 2022. The FDA's Drug Shortage Database has tracked intermittent shortages of amphetamine-based products, including lisdexamfetamine, driven by DEA manufacturing quota limits and raw material constraints [15]. If your local CVS, Walgreens, or Rite Aid is out of stock, consider these alternatives:

• Independent pharmacies: smaller volumes sometimes mean more reliable supply chains.
• 503A compounding pharmacies: New Hampshire-licensed 503A pharmacies can compound lisdexamfetamine when a patient-specific prescription is provided. Compounded product will differ in excipients and may not be therapeutically equivalent to the brand.
• Mail-order pharmacy: some insurers offer 90-day supplies at reduced copays through preferred mail-order networks.

Generic lisdexamfetamine became available in August 2023 after Takeda's patent settlement allowed several manufacturers (including Alvogen and Sandoz) to enter the market [16]. Generic pricing runs 40% to 60% lower than brand Vyvanse, with cash prices typically between $150 and $280 for a 30-day supply.

Cost-Saving Strategies for New Hampshire Patients

Without insurance, brand Vyvanse costs $350 to $450 per month at most NH retail pharmacies. Several strategies can reduce that number substantially.

Takeda's patient assistance program (Help at Hand) provides free Vyvanse to uninsured or underinsured patients whose household income falls below 250% of the federal poverty level [17]. Applications are processed through the prescriber's office and typically take 4 to 6 weeks for approval.

Manufacturer copay cards reduce commercially insured copays to as low as $30 per month, though patients on government insurance (Medicaid, Medicare, TRICARE) are ineligible by federal anti-kickback statute. The current Vyvanse Savings Program caps annual benefits at $3,600 [17].

GoodRx, RxSaver, and similar discount aggregators frequently list generic lisdexamfetamine below $200 at NH pharmacies such as Costco (Nashua), Walmart (multiple locations), and independent compounding pharmacies.

NH-specific resources: the NH Rx Assistance Program (ServiceLink at 1-866-634-9412) connects residents with manufacturer programs, state discount initiatives, and Medicare Extra Help for older adults with ADHD. The Endocrine Society's 2024 clinical practice guideline on stimulant therapy notes that cost barriers remain a primary reason for treatment discontinuation, particularly in states where Medicaid formularies exclude branded stimulants [18].

Telehealth-Specific Considerations for NH Residents

Telehealth has expanded ADHD treatment access in rural NH counties (Coos, Grafton, Carroll) where psychiatric providers are sparse. The Health Resources and Services Administration designates much of northern New Hampshire as a Mental Health Professional Shortage Area [19].

When choosing a telehealth provider, verify the following:

• The provider holds an active NH license (check the NH Board of Medicine or Board of Nursing online lookup).
• The platform uses EPCS-certified software for Schedule II transmission.
• The provider checks the NH PDMP before each prescription, as required by RSA 318-B:31-a [14].
• Follow-up visits are scheduled every 30 to 90 days during dose titration, then every 3 to 6 months once stable, consistent with APA practice guidelines [20].

A 2023 JAMA Network Open study (N=17,457) found that telehealth-initiated stimulant prescriptions had comparable continuation rates and adverse event profiles to in-person-initiated prescriptions at 12 months, supporting the clinical validity of this pathway [21].

Transferring a Vyvanse Prescription to New Hampshire

If you are relocating to NH from another state, your existing Vyvanse prescription cannot simply be "transferred" the way a non-controlled medication can. Federal law prohibits transferring Schedule II prescriptions between pharmacies [2]. You will need:

1. A new prescription from a provider licensed in New Hampshire, OR
2. Your current out-of-state provider to issue a new prescription to an NH pharmacy (permissible if the provider also holds NH licensure or qualifies under temporary telehealth reciprocity).

Bring your medical records, including ADHD evaluation documentation, rating scales, medication history, and a letter from your previous provider. This speeds the process and can eliminate the need to repeat a full diagnostic workup.

Monitoring and Follow-Up Requirements

Once on Vyvanse, ongoing monitoring should include blood pressure and heart rate at each visit, periodic weight checks (lisdexamfetamine carries a mean weight loss of 2.3 kg in adult ADHD trials), and screening for cardiovascular symptoms [1]. The FDA label includes a boxed warning about potential for misuse and dependence common to all amphetamine-class stimulants [1].

The AACAP recommends at least two follow-up visits in the first month after initiation, then quarterly for stable patients, with annual reassessment of whether continued treatment is warranted [22]. NH-specific PDMP rules require the prescriber to review the patient's controlled substance history at least annually, though most providers check at every visit [14].

Growth monitoring in pediatric patients is especially important. Wigal et al. Reported modest height velocity reductions (approximately 1 cm/year below expected) in children on lisdexamfetamine over 2 years, with partial catch-up after discontinuation [3]. Drug holidays during summer or school breaks may be considered when clinically appropriate.